Brainstorm Cell Therapeutics (BCLI) Treats Final Patient in NurOwn Phase 2
Tweet Send to a Friend
Brainstorm Cell Therapeutics (NASDAQ: BCLI) announced today that the final patient has been treated in its multicenter Phase 2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
